Contraline has secured $92.5 million in Series B funding, co-led by BVF Partners L.P. and RA Capital Management, marking a significant follow-on round for the clinical-stage biopharmaceutical company. This capital infusion will accelerate the development of their novel male contraceptives, with plans to advance their lead product through clinical trials. The round also saw participation from GV (Google Ventures) and Lumira Ventures, among others.